Koch Hein EC, et al. Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world experience from a Canadian comprehensive cancer centre. Cancers 2023; 15:4312. doi: 10.3390/cancers15174312
Carroll RP, et al. Immune checkpoint inhibitors in kidney transplant recipients: A multicentre, single-arm, phase 1 study. Lancet Oncol 2022; 23:1078–1086. doi: 10.1016/S1470-2045(22)00368-0
Barnett R, et al. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med 2017; 376:191–192. doi: 10.1056/NEJMc1614298
Schenk KM, et al. Nivolumab + tacrolimus + prednisone ± ipilimumab for kidney transplant recipients with advanced cutaneous cancers. J Clin Oncol 2024; 42:1011–1020. doi: 10.1200/JCO.23.01497
Hanna GJ, et al. Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma. J Clin Oncol 2024; 42:1021–1030. doi: 10.1200/JCO.23.01498